| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| MB-101 (Mustang Bio) | MB-101 | Phase 1 Clinical | City Of Hope National Medical Center, Mustang Bio Inc | Brain Neoplasms; CNS Embryonal Tumor; Glioblastoma; Glioma | Details |
| IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Adenocarcinoma of Lung; Adenoma, Islet Cell; Adrenocortical Carcinoma; Breast Neoplasms; Ependymoma; Glioblastoma; Medulloblastoma; Melanoma; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Thyroid Neoplasms; Uveal melanoma | Details | |
| E-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine) | Phase 1 Clinical | University Of California San Francisco | Glioblastoma | Details | |
| EPC-003 | EPC-003 | Phase 1 Clinical | Elpis BioPharmaceuticals Corp | Glioblastoma; Multiple Myeloma | Details |
| IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody therapy (Emergency General Hospital) | Phase 1 Clinical | Emergency General Hospital, Department of Neurosurgery | Glioma | Details | |
| IL13Rα2 targeted CAR-T cell(Yooyoung) | YYB-103; CLM-103 | Phase 1 Clinical | YooYoung Pharmaceutical Co Ltd | Amyotrophic Lateral Sclerosis; Glioma | Details |
| Autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells Therapy(City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Astrocytoma; Glioblastoma | Details | |
| MT-026 | MT-026 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |